Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › HRS9531-T-201 oral ribupatide (NCT06841445)

HRS9531-T-201 oral ribupatide (NCT06841445)

Ribupatide (HRS9531) · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Ribupatide (HRS9531)
Population
obesity
Phase
2
Participants
166
Duration
26 weeks
Registry
NCT06841445

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
10 mg oral QDobesity china26166−6.9 % vs −2.3 %
Δ −4.6 pp
−6.7 % vs −2.1 %
Δ −4.6 pp
—0.0 vs 0.0—11.9 vs 7.52.4 vs 0.02.4 vs 2.5−6.1 vs −3.9press release
25 mg oral QDobesity china26166−12.1 % vs −2.3 %
Δ −9.8 pp
−11.9 % vs −2.1 %
Δ −9.8 pp
—0.0 vs 0.0—22.7 vs 7.511.4 vs 0.04.5 vs 2.5−6.4 vs −3.9press release
50 mg oral QDobesity china26166−12.1 % vs −2.3 %
Δ −9.8 pp
−11.4 % vs −2.1 %
Δ −9.3 pp
—2.5 vs 0.0—20.0 vs 7.57.5 vs 0.00.0 vs 2.5−5.1 vs −3.9press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (21)
  • 10 mg oral QD · weight_tp · press release
    Based on the treatment policy estimand^II at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.7% (10 mg), 11.9% (25 mg), and 11.4% (50 mg)
  • 10 mg oral QD · nausea · abstract
    Nausea 5 (11.9) 10 (22.7) 8 (20.0) 3 (7.5)
  • 10 mg oral QD · vomiting · abstract
    Vomiting 1 (2.4) 5 (11.4) 3 (7.5) 0
  • 10 mg oral QD · sae · abstract
    SAEs* 1 (2.4) 2 (4.5) 0 1 (2.5)
  • 10 mg oral QD · ae_dc · abstract
    TEAEs leading to treatment discontinuation 0 0 1 (2.5)# 0
  • 10 mg oral QD · sbp · abstract
    SBP, mmHg, LS mean (SE) -6.1 (1.4) -6.4 (1.3) -5.1 (1.4) -3.9 (1.5)
  • 10 mg oral QD · weight_eff · press release
    Based on the efficacy estimand^I at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.9% (10 mg), 12.1% (25 mg), and 12.1% (50 mg)
  • 25 mg oral QD · weight_tp · press release
    Based on the treatment policy estimand^II at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.7% (10 mg), 11.9% (25 mg), and 11.4% (50 mg)
  • 25 mg oral QD · nausea · abstract
    Nausea 5 (11.9) 10 (22.7) 8 (20.0) 3 (7.5)
  • 25 mg oral QD · vomiting · abstract
    Vomiting 1 (2.4) 5 (11.4) 3 (7.5) 0
  • 25 mg oral QD · sae · abstract
    SAEs* 1 (2.4) 2 (4.5) 0 1 (2.5)
  • 25 mg oral QD · ae_dc · abstract
    TEAEs leading to treatment discontinuation 0 0 1 (2.5)# 0
  • 25 mg oral QD · sbp · abstract
    SBP, mmHg, LS mean (SE) -6.1 (1.4) -6.4 (1.3) -5.1 (1.4) -3.9 (1.5)
  • 25 mg oral QD · weight_eff · press release
    Based on the efficacy estimand^I at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.9% (10 mg), 12.1% (25 mg), and 12.1% (50 mg)
  • 50 mg oral QD · weight_tp · press release
    Based on the treatment policy estimand^II at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.7% (10 mg), 11.9% (25 mg), and 11.4% (50 mg)
  • 50 mg oral QD · nausea · abstract
    Nausea 5 (11.9) 10 (22.7) 8 (20.0) 3 (7.5)
  • 50 mg oral QD · vomiting · abstract
    Vomiting 1 (2.4) 5 (11.4) 3 (7.5) 0
  • 50 mg oral QD · sae · abstract
    SAEs* 1 (2.4) 2 (4.5) 0 1 (2.5)
  • 50 mg oral QD · ae_dc · abstract
    TEAEs leading to treatment discontinuation 0 0 1 (2.5)# 0
  • 50 mg oral QD · sbp · abstract
    SBP, mmHg, LS mean (SE) -6.1 (1.4) -6.4 (1.3) -5.1 (1.4) -3.9 (1.5)
  • 50 mg oral QD · weight_eff · press release
    Based on the efficacy estimand^I at Week 26, participants taking oral ribupatide achieved a mean weight loss of 6.9% (10 mg), 12.1% (25 mg), and 12.1% (50 mg)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: HRS9531-T-201 oral ribupatide (NCT06841445). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs9531-t-201-oral-ribupatide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.